FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2983006876> ?p ?o ?g. }

• W2983006876 endingPage "811" @default.
• W2983006876 startingPage "802" @default.
• W2983006876 abstract "Abstract Introduction This study investigates the outcomes and safety of 70–150 μm and 100–300 μm doxorubicin drug‐eluting bead transarterial chemoembolisation (DEB‐TACE) in patients with unresectable hepatocellular carcinoma (HCC). Methods Retrospective, cohort study of 51 patients treated with DEB‐TACE for unresectable HCC was studied: 23 with 100–300 μm particles and 28 with 70–150 μm particles. Overall, survival (OS), progression‐free survival (PFS), tumour response and prognostic factors were assessed. Results The median OS of the entire cohort was 30 months. The median OS and median PFS for 70–150 μm particles were not reached, whilst for the 100–300 μm group, it was 29.2 months and 15.0 months, respectively. The 6‐month, 1‐year and 2‐year OS for 70–150 μm was 96%, 86% and 85% versus the 100–300 μm particles size of 83%, 64% and 44%, respectively. At 1‐month follow‐up, patients treated with 70–150 μm had significantly better mRECIST tumour response compared to 100–300 μm (complete response 38.5% vs. 19%; partial response 57.7% vs. 42.9%; stable disease 0% vs. 4.8%; progressive disease 3.8% vs. 33.3%, P = 0.027). Patients treated with 100–300 μm DEBs were significantly more likely to have progressive disease on 1‐month follow‐up imaging compared those treated with 70–150 μm DEB sizes (odds ratio 7.15, P = 0.007). The 30‐day mortality rate was similar between the two groups (3.6% for 70–150 μm vs. 4.3% for 100–300 μm). Multivariate analysis demonstrated entire cohort OS was significantly associated with BCLC stage (aHR: 10.5, P = 0.002), albumin (aHR: 15.0, P = 0.02) and ALP (aHR 62, P = 0.001). Conclusions DEB‐TACE with 70–150 μm particles demonstrates improved 1‐month objective tumour response compared to 100–300 μm, whilst having a similar safety profile. Elevated ALP, lower albumin and higher BCLC stage were significantly associated with poorer survival outcomes." @default.
• W2983006876 created "2019-11-22" @default.
• W2983006876 creator A5041673005 @default.
• W2983006876 creator A5048341933 @default.
• W2983006876 creator A5056139435 @default.
• W2983006876 creator A5081627781 @default.
• W2983006876 date "2019-11-10" @default.
• W2983006876 modified "2023-10-16" @default.
• W2983006876 title "Survival, tumour response and safety of 70‐150 μm versus 100‐300 μm doxorubicin drug‐eluting beads in transarterial chemoembolisation for hepatocellular carcinoma" @default.
• W2983006876 cites W1853573159 @default.
• W2983006876 cites W1963919405 @default.
• W2983006876 cites W1972581725 @default.
• W2983006876 cites W1988244199 @default.
• W2983006876 cites W1990026158 @default.
• W2983006876 cites W1990404563 @default.
• W2983006876 cites W1993128964 @default.
• W2983006876 cites W1997111874 @default.
• W2983006876 cites W1998618098 @default.
• W2983006876 cites W2007991329 @default.
• W2983006876 cites W2020830322 @default.
• W2983006876 cites W2031009337 @default.
• W2983006876 cites W2031318932 @default.
• W2983006876 cites W2036304264 @default.
• W2983006876 cites W2050344385 @default.
• W2983006876 cites W2055037251 @default.
• W2983006876 cites W2059377623 @default.
• W2983006876 cites W2065881192 @default.
• W2983006876 cites W2069793759 @default.
• W2983006876 cites W2072077758 @default.
• W2983006876 cites W2079586464 @default.
• W2983006876 cites W2086051607 @default.
• W2983006876 cites W2088517081 @default.
• W2983006876 cites W2092759077 @default.
• W2983006876 cites W2093580610 @default.
• W2983006876 cites W2097287859 @default.
• W2983006876 cites W2098618036 @default.
• W2983006876 cites W2106326747 @default.
• W2983006876 cites W2109755757 @default.
• W2983006876 cites W2127454023 @default.
• W2983006876 cites W2132717325 @default.
• W2983006876 cites W2137052325 @default.
• W2983006876 cites W2138059780 @default.
• W2983006876 cites W2138431776 @default.
• W2983006876 cites W2142426633 @default.
• W2983006876 cites W2163486683 @default.
• W2983006876 cites W2166921085 @default.
• W2983006876 cites W2171673899 @default.
• W2983006876 cites W2225797292 @default.
• W2983006876 cites W2239273775 @default.
• W2983006876 cites W2284586115 @default.
• W2983006876 cites W2323858893 @default.
• W2983006876 cites W2329042838 @default.
• W2983006876 cites W2755234203 @default.
• W2983006876 doi "https://doi.org/10.1111/1754-9485.12971" @default.
• W2983006876 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31709778" @default.
• W2983006876 hasPublicationYear "2019" @default.
• W2983006876 type Work @default.
• W2983006876 sameAs 2983006876 @default.
• W2983006876 citedByCount "15" @default.
• W2983006876 countsByYear W29830068762020 @default.
• W2983006876 countsByYear W29830068762021 @default.
• W2983006876 countsByYear W29830068762022 @default.
• W2983006876 countsByYear W29830068762023 @default.
• W2983006876 crossrefType "journal-article" @default.
• W2983006876 hasAuthorship W2983006876A5041673005 @default.
• W2983006876 hasAuthorship W2983006876A5048341933 @default.
• W2983006876 hasAuthorship W2983006876A5056139435 @default.
• W2983006876 hasAuthorship W2983006876A5081627781 @default.
• W2983006876 hasConcept C126322002 @default.
• W2983006876 hasConcept C156957248 @default.
• W2983006876 hasConcept C167135981 @default.
• W2983006876 hasConcept C2776694085 @default.
• W2983006876 hasConcept C2778019345 @default.
• W2983006876 hasConcept C2778822529 @default.
• W2983006876 hasConcept C2779984678 @default.
• W2983006876 hasConcept C2781303535 @default.
• W2983006876 hasConcept C3019096185 @default.
• W2983006876 hasConcept C71924100 @default.
• W2983006876 hasConcept C72563966 @default.
• W2983006876 hasConcept C90924648 @default.
• W2983006876 hasConceptScore W2983006876C126322002 @default.
• W2983006876 hasConceptScore W2983006876C156957248 @default.
• W2983006876 hasConceptScore W2983006876C167135981 @default.
• W2983006876 hasConceptScore W2983006876C2776694085 @default.
• W2983006876 hasConceptScore W2983006876C2778019345 @default.
• W2983006876 hasConceptScore W2983006876C2778822529 @default.
• W2983006876 hasConceptScore W2983006876C2779984678 @default.
• W2983006876 hasConceptScore W2983006876C2781303535 @default.
• W2983006876 hasConceptScore W2983006876C3019096185 @default.
• W2983006876 hasConceptScore W2983006876C71924100 @default.
• W2983006876 hasConceptScore W2983006876C72563966 @default.
• W2983006876 hasConceptScore W2983006876C90924648 @default.
• W2983006876 hasIssue "6" @default.
• W2983006876 hasLocation W29830068761 @default.
• W2983006876 hasLocation W29830068762 @default.
• W2983006876 hasOpenAccess W2983006876 @default.
• W2983006876 hasPrimaryLocation W29830068761 @default.
• W2983006876 hasRelatedWork W1591915866 @default.

• next